宗旨和范围
Expert Opinion on Emerging Drugs is a quarterly peer-reviewed medical journal publishing structured reviews on drugs/drug classes emerging onto the market across all therapy areas. Each review includes an "expert opinion" section, in which authors are asked to provide their personal view on the current status and future direction of the research discussed. It was established as Emerging Drugs in 1996, changing to its current name in 2001. It is published by Informa. According to the Journal Citation Reports, the journal has a 2014 impact factor of 3.058. Less
关键指标
期刊详情
- 出版商TAYLOR & FRANCIS LTD
- 出版语言English
- 出版频率Quarterly
- 出版语言English
- 出版频率Quarterly
- 创刊年份2001
- Publisher URL
- 网址
准备好展示你的研究成果了吗?
解锁专业图文摘要的强大优势:
Topics Covered on Expert Opinion on Emerging Drugs
常见问题
Expert Opinion on Emerging Drugs 是从何时开始发行的? 
Expert Opinion on Emerging Drugs 自2001开始发行至今。
Expert Opinion on Emerging Drugs 多久发行一次? 
Expert Opinion on Emerging Drugs 为Quarterly。
Expert Opinion on Emerging Drugs 的 H 指数、SNIP 指数、Citescore 和 SJR 分别是多少? 
Expert Opinion on Emerging Drugs 的H指数为 52、 Citescore 为 5.6、SNIP 指数为0.8 、 SJR 为 Q1。
Expert Opinion on Emerging Drugs 的出版商是谁? 
Expert Opinion on Emerging Drugs 的出版商是TAYLOR & FRANCIS LTD。
我在哪里查看 Expert Opinion on Emerging Drugs 的宗旨和范围? 
查看 Expert Opinion on Emerging Drugs 的宗旨和范围,请点击此处。
我如何在意得辑上查看Expert Opinion on Emerging Drugs 的指标? 
查看 Expert Opinion on Emerging Drugs 的指标,请单击此处。
Expert Opinion on Emerging Drugs 的 eISSN和pISSN 号分别是什么? 
1744-7623 的 eISSN 为 1472-8214,pISSN 为 Expert Opinion on Emerging Drugs 。
该期刊重点关注哪些主题? 
本期刊关注的主题范围广泛,包括 [object Object], [object Object], [object Object], [object Object], [object Object], [object Object], [object Object], [object Object], [object Object], [object Object], [object Object], [object Object], [object Object], [object Object], [object Object], [object Object], [object Object]。
为什么搜索适合我研究的期刊很重要? 
选择与您研究领域紧密相关的期刊,有助于确保您的学术成果能够触及最合适的读者群体, 从而最大化您的学术影响力和对该领域的贡献。
对期刊的选择会影响我的学术事业吗? 
当然。在知名期刊上发表论文可提升您的学术形象, 使您在获取资助、终身教职和其他职业机会方面更具竞争力。
只考虑具有高影响力的期刊是否明智? 
虽然高影响力的期刊知名度高,但投稿竞争也相对激烈。因此, 关键在于权衡考虑期刊的影响因子与论文被接受的可能性。